Kissei Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company headquartered in Matsumoto, Nagano Prefecture, Japan, founded in 1946. The company specializes in the development of pharmaceuticals for urology, neurology, and immunology, with a growing focus on central nervous system disorders including Parkinson's disease and other neurodegenerative conditions [1].
The company has established partnerships with international biotech firms to expand its neuroscience pipeline and has invested in novel drug delivery technologies for CNS disorders [2].
| Program | Target/Mechanism | Indication | Phase | Status |
|---|---|---|---|---|
| Naldemedine | Peripheral μ-opioid receptor antagonist | Opioid-induced constipation | Approved (Japan/US/EU) | Marketed |
| Sultamicillin | Antibiotic | Bacterial infections | Approved | Marketed |
| KL-014 | Disease-modifying therapy | Parkinson's disease | Preclinical | Research |
| KL-028 | α-synuclein aggregation inhibitor | Parkinson's disease | Discovery | Research |
| KW-6800 | Dopamine stabilizer | Parkinson's disease | Discovery | Research |
Kissei's neuroscience research programs target:
Kissei has established partnerships with:
Kissei Pharmaceutical maintains a strong position in the Japanese pharmaceutical market, particularly in the urology and neurology segments. The company's focus on niche therapeutic areas has allowed it to establish leadership positions without competing directly with major pharmaceutical companies [1].
The company's domestic market presence is complemented by international partnerships that provide access to global markets. Kissei's strategy emphasizes partnerships over direct commercialization in international markets [2].
Kissei operates manufacturing facilities in Matsumoto, Nagano Prefecture, which produce both active pharmaceutical ingredients and finished dosage forms. The facilities maintain GMP certification and have been inspected by regulatory authorities in Japan, the United States, and Europe [1].
Kissei is committed to corporate social responsibility initiatives in healthcare access, environmental sustainability, and community engagement. The company supports healthcare programs in developing countries and participates in industry-wide initiatives to improve pharmaceutical accessibility [3].
Looking forward, Kissei Pharmaceutical aims to become a leading neuroscience company in Japan. The company's strategy includes: